The medical journal Annals of Pharmacotherapy has published an article, “Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis”, which concludes that dipeptidyl peptidase-4 (DPP-4) inhibitors increase the risk of Crohn’s disease (CD). It goes on to point out that these DPP-4 inhibitor diabetes drugs, such as … [Read more...]
Certain Diabetes Drugs Like Januvia Associated With Bile Duct Cancer
The risk of developing bile duct cancer, also known as cholangiocarcinoma, is almost doubled for type 2 diabetics using one of the following diabetes medicines: Januvia (sitagliptin) Janumet (sitagliptin / metformin HCl) Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin) Qtern (dapagliflozin and saxagliptin) Nesina … [Read more...]
Type 2 Diabetes Drugs Linked to Severe Joint Pain
Health Canada recently warned about the risk of severe, debilitating joint pain as a result of taking type 2 diabetes medications called dipeptidylpeptidase-4 (DPP-4) inhibitors. This DPP-4 inhibitors class of drugs includes the following: Onglyza Kombiglyze XR Nesina Kazano Oseni Glyxambi Janumet (XR) Januvia … [Read more...]